Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for Q2 2021 on July 29, 2021, after market close. An investor conference call will follow at 5:00 p.m. Eastern time on the same day. The call can be accessed domestically at (844) 578-9672 and internationally at (508) 637-5656, with a live webcast available on merit.com. Founded in 1987, Merit manufactures disposable medical devices for interventional procedures and serves clients worldwide, employing about 6,500 people across multiple global locations.
Merit Medical Systems (NASDAQ: MMSI) reported Q1 2021 revenue of $248.9 million, up 2.2% from Q1 2020. The GAAP EPS stood at $0.19, a turnaround from a loss of ($0.06) in the previous year. Non-GAAP EPS increased to $0.52 from $0.38. The company's GAAP gross margin was 45.0%, up from 42.6% year-over-year. A strong cash flow of $29 million was generated. For FY 2021, Merit forecasts net revenue between $994 million and $1,014 million, anticipating modest growth in the cardiovascular and endoscopy segments.
Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its Q1 financial results for the period ending March 31, 2021, on April 29, 2021, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day, with details available on their website. Founded in 1987, Merit specializes in disposable medical devices for interventional procedures across various fields, including cardiology and oncology, serving a global client base.
SOUTH JORDAN, Utah, April 08, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI), a leader in disposable medical devices for interventional, diagnostic, and therapeutic procedures, will participate in the 20th Annual Needham Healthcare Conference. The event is set for April 15 at 2:15 p.m. ET, featuring a fireside chat with CEO Fred Lampropoulos and CFO Raul Parra. Merit Medical, headquartered in Utah, operates globally with a workforce of about 6,000, catering to hospitals and healthcare facilities across various regions.
Merit Medical Systems (NASDAQ: MMSI) has initiated its pivotal WAVE Study to assess the safety and effectiveness of the WRAPSODY Endovascular Stent Graft for treating dialysis outflow circuit stenosis or occlusion. The first two patients have been enrolled at RAC Surgery Center, Raleigh, NC. This multicenter study aims to recruit 357 patients across the U.S., Europe, Canada, and New Zealand, with a two-year follow-up. The WRAPSODY system, already holding a CE Mark, is designed to improve vascular access in over two million global hemodialysis patients, addressing common complications in dialysis procedures.
Merit Medical Systems reported Q4 2020 revenue of $258.0 million, nearly flat compared to Q4 2019. The company experienced a 1.0% decline in core revenue on a constant currency basis. The Q4 GAAP EPS stood at $0.27, recovering from a loss of ($0.08) the previous year. Non-GAAP EPS rose to $0.54 from $0.40. For the full year, revenue was $963.9 million, down 3.1%, while GAAP net income for Q4 was $15.4 million. Merit forecasts 2021 revenue between $990 million and $1.01 billion, reflecting a cautious optimism for recovery.
Merit Medical Systems (NASDAQ: MMSI) will announce its fourth quarter and year-end financial results for 2020 on February 24, 2021, after the market closes. Investors can participate in a conference call on the same day at 5:00 p.m. Eastern via telephone or live webcast. The company specializes in manufacturing disposable medical devices for cardiology, radiology, oncology, and other therapeutic areas. With approximately 6,000 employees globally, Merit has a strong presence in various countries, including the USA, France, and China.
Merit Medical Systems (NASDAQ: MMSI) announced its participation in the 2021 SVB Leerink Global Healthcare Conference.
The conference will be held virtually on February 25, 2021, at 2:20 p.m. ET. CEO Fred P. Lampropoulos and CFO Raul Parra will present and host one-on-one meetings.
Founded in 1987, Merit specializes in manufacturing disposable medical devices for various medical fields, employing approximately 6,000 individuals worldwide.
Merit Medical Systems, a leading manufacturer of disposable medical devices, announced participation in two upcoming virtual investor conferences. On January 13, at 2:00 p.m. ET, CEO Fred P. Lampropoulos and CFO Raul Parra will present at the 23rd Annual Needham Growth Conference. The following day, January 14, at 2:30 p.m. ET, they will host a fireside chat at the ICR Conference 2021. Both events will include virtual one-on-one meetings with investors.
SOUTH JORDAN, Utah, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI) will hold an investor call today to discuss multi-year financial targets from 2020 to 2023. Key targets include a compound annual growth rate (CAGR) of 5%-7% in revenue, a GAAP operating margin of 13.7%-17.0%, and a non-GAAP operating margin of 18%-21%. The company estimates 2020 net revenue between $950 million and $959 million, a decline from $994.9 million in 2019. GAAP net loss is forecasted between $(11.8) million and $(15.0) million.